Every source named. Every signal weight published.
The competitor set treats data provenance like a moat. PharmaCliff treats it like a checklist. If a verdict goes in front of a Director of IP, the ingest path is owed to them.
Pharma + biotech, CPC-pre-filtered against 14 therapeutic-area anchors.
Linked to live ANDA opportunities — real generic-launch candidates.
INPADOC family linkage adds IN, CN, BR reach when a family member is present.
Indexes refresh daily. Digest assembled Monday, AI-scored, subscriber feedback tunes the next rubric.
01Curation pipeline
Four stages, fully automated, no human pre-send review:
- CPC pre-filter. Every new patent is matched against 14 therapeutic-area anchors (CPC class prefixes). Non-matches drop out.
- AI scoring. Each matched patent gets scored against the five signals (see §02). Temperature 0 — deterministic.
- Verdict bands. Score 0–100 maps to HIGH (≥ 75), MEDIUM (50–74), LOW (< 50).
- Subscriber feedback. Thumbs-down clicks on email rows or dashboard rows are reviewed and used to tune the next rubric version. No silent re-scoring of past digests.
PharmaCliff is curated by AI scoring, not by hand. The founder is not personally reviewing every HIGH-verdict row before send — claims to the contrary on any page are wrong. The honest framing: AI scores, subscriber feedback corrects, rubric improves.
02Verdict logic
Five signals, weighted into a 0–100 score:
| Signal | Weight | What it captures |
|---|---|---|
| Orange Book ANDA route | 25 | Patent is associated with an NDA + has a visible ANDA pathway (generic submission slot). |
| INPADOC family convergence | 20 | How many jurisdictions in the family cliff within the same 12-month window. |
| Claim breadth | 20 | Composition-of-matter (broad) ranks higher than method-of-use or formulation (narrow). |
| Time-to-expiry | 20 | Closer expiries score higher — the digest is for decisions you can act on this quarter or next. |
| TA-anchor match strength | 15 | Strong CPC-anchor matches in your tracked areas outrank tangential matches. |
Holder name is removed from the scoring prompt to prevent bias. Same patent + same rubric version → same score, always.
03Known limitations
- Beta AI. Rubric weights are still being tuned. First 20–50 subscribers will see imperfect rankings before convergence.
- No real-time USPTO grant feed. New grants land in the index within a week of publication, not within minutes.
- No human pre-send review. AI scores every row autonomously. Subscriber feedback is the correction loop.
- Excludes medical devices, diagnostics, veterinary pharma, agrochemicals, cannabis, and consumer-health formulations without a CPC anchor match.
04Data handling
Personal data stored: email + therapeutic-area selections + jurisdiction selections. Hosted on Neon Postgres in Frankfurt (EU). Email delivery via Resend (also EU infrastructure when possible). GDPR data export and deletion endpoints in account settings. Full details in the privacy policy.